Global New Traditional Chinese Medicine Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global New Traditional Chinese Medicine Market Insights, Forecast to 2034
New Traditional Chinese Medicine refers to a new type of medicine developed through innovative research and development based on traditional Chinese medicine or Chinese herbal formulations. It may contain not only the traditional Chinese medicine ingredients, but also synthetic chemical Compounds or natural substances, as well as processed and extracted Chinese medicine ingredients. The research and development of Chinese medicine innovative drugs follows the standards and procedures of modern drug development, using modern scientific techniques to screen, extract, and isolate the ingredients of Chinese herbal formula ations in order to achieve more significant therapeutic effects, fewer side effects, and better absorption and utilization by the human body. The development of these drugs plays an important role in promoting the modernization and internationalization of traditional Chinese medicine.
Market Analysis and InsightsGlobal New Traditional Chinese Medicine Market
Global New Traditional Chinese Medicine market is expected to reach to US$ 3721 million in 2024, with a positive growth of %, compared with US$ 3561 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, New Traditional Chinese Medicine industry is evaluated to reach US$ 5072.6 million in 2034. The CAGR will be 5.3% during 2024 to 2034.
Globally, New Traditional Chinese Medicine key companies include Yiling Pharmaceutical, Kanion Pharmaceutical, Tasly, Yangtze River Pharmaceutical, Hutchison, ApicHope, Jiangzhong Pharmaceutical, Buchang Pharma and Guizhou Bailing, etc. Yiling Pharmaceutical, Kanion Pharmaceutical, Tasly are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of New Traditional Chinese Medicine were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034 and the share will be % in 2034. Moreover, China, plays a key role in the whole New Traditional Chinese Medicine market and estimated to attract more attentions from industry insiders and investors.
New Traditional Chinese Medicine can be divided into Innovative Traditional Chinese Medicine, Improved New Drug of Traditional Chinese Medicine and Traditional Chinese Medicine Compound Preparation,, etc. Innovative Traditional Chinese Medicine is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2034.
New Traditional Chinese Medicine is widely used in various fields, such as Online Sales and Offline Sales, etc. Online Sales provides greatest supports to the New Traditional Chinese Medicine industry development. In 2022, global % revenue of New Traditional Chinese Medicine went into Online Sales filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global New Traditional Chinese Medicine market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global New Traditional Chinese Medicine market with multiple angles. Items like regional revenue from 2018 to 2034 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Yiling Pharmaceutical
Kanion Pharmaceutical
Tasly
Yangtze River Pharmaceutical
Hutchison
ApicHope
Jiangzhong Pharmaceutical
Buchang Pharma
Guizhou Bailing
Zhangzhou Pien Tze Huang Pharmaceutical
Jumpcan Pharmaceutical
Xiangxue Pharma
KPC Pharmaceutical
CONSUN
Huluwa Pharmaceutical
Fangsheng Pharma
BaiYunShan
Segment by Type
Innovative Traditional Chinese Medicine
Improved New Drug of Traditional Chinese Medicine
Traditional Chinese Medicine Compound Preparation
Online Sales
Offline Sales
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2034
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2034 globally
Chapter 5Product revenue analysis by application from 2018 to 2034 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2034 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product revenue analysis by type and application from 2018 to 2034 in Europe. Product revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product revenue analysis by type and application from 2018 to 2034 in China. Product revenue analysis of China from 2018 to 2034
Chapter 9Product revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Companies’ outline, covering company’s basic information, major business, New Traditional Chinese Medicine introduction, etc. New Traditional Chinese Medicine Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12QYResearch’s Conclusions of New Traditional Chinese Medicine
Chapter 13Methodology and Data Sources adopted by QYResearch
Market Analysis and InsightsGlobal New Traditional Chinese Medicine Market
Global New Traditional Chinese Medicine market is expected to reach to US$ 3721 million in 2024, with a positive growth of %, compared with US$ 3561 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, New Traditional Chinese Medicine industry is evaluated to reach US$ 5072.6 million in 2034. The CAGR will be 5.3% during 2024 to 2034.
Globally, New Traditional Chinese Medicine key companies include Yiling Pharmaceutical, Kanion Pharmaceutical, Tasly, Yangtze River Pharmaceutical, Hutchison, ApicHope, Jiangzhong Pharmaceutical, Buchang Pharma and Guizhou Bailing, etc. Yiling Pharmaceutical, Kanion Pharmaceutical, Tasly are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of New Traditional Chinese Medicine were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034 and the share will be % in 2034. Moreover, China, plays a key role in the whole New Traditional Chinese Medicine market and estimated to attract more attentions from industry insiders and investors.
New Traditional Chinese Medicine can be divided into Innovative Traditional Chinese Medicine, Improved New Drug of Traditional Chinese Medicine and Traditional Chinese Medicine Compound Preparation,, etc. Innovative Traditional Chinese Medicine is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2034.
New Traditional Chinese Medicine is widely used in various fields, such as Online Sales and Offline Sales, etc. Online Sales provides greatest supports to the New Traditional Chinese Medicine industry development. In 2022, global % revenue of New Traditional Chinese Medicine went into Online Sales filed and the proportion will reach to % in 2034.
Report Covers
This report presents an overview of global New Traditional Chinese Medicine market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global New Traditional Chinese Medicine market with multiple angles. Items like regional revenue from 2018 to 2034 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Yiling Pharmaceutical
Kanion Pharmaceutical
Tasly
Yangtze River Pharmaceutical
Hutchison
ApicHope
Jiangzhong Pharmaceutical
Buchang Pharma
Guizhou Bailing
Zhangzhou Pien Tze Huang Pharmaceutical
Jumpcan Pharmaceutical
Xiangxue Pharma
KPC Pharmaceutical
CONSUN
Huluwa Pharmaceutical
Fangsheng Pharma
BaiYunShan
Segment by Type
Innovative Traditional Chinese Medicine
Improved New Drug of Traditional Chinese Medicine
Traditional Chinese Medicine Compound Preparation
Segment by Application
Online Sales
Offline Sales
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2034
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2034 globally
Chapter 5Product revenue analysis by application from 2018 to 2034 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2034 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product revenue analysis by type and application from 2018 to 2034 in Europe. Product revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product revenue analysis by type and application from 2018 to 2034 in China. Product revenue analysis of China from 2018 to 2034
Chapter 9Product revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Companies’ outline, covering company’s basic information, major business, New Traditional Chinese Medicine introduction, etc. New Traditional Chinese Medicine Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12QYResearch’s Conclusions of New Traditional Chinese Medicine
Chapter 13Methodology and Data Sources adopted by QYResearch